Technical analyst Salil Sharma has maintained 'buy' rating on Ranbaxy Laboratories Limited stock with a target of Rs 580.

According to analyst, the investors can buy the stock with a stop loss of Rs 560.

The stock of the company, on December 06, closed at Rs 568.25 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 624.90 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 24.34 and 23.38 respectively.

Ranbaxy Laboratories has bagged the final nod from the USFDA to make and sell donepezil hydrochloride, the generic edition of Aricept tabs in the potencies of 5 mg and 10 mg.

The overall twelve-monthly market sales for Aricept 5 mg and 10 mg tabs stood at $2.6 billion.

Ranbaxy Laboratories said that its profit after tax and minority interest for the three month period ended Sept 30 stood at Rs 3,079.36 million as compared to Rs 1,145.31 million for the same period f 2009.

Company's total income surged 12.38% to Rs 21,376.23 million for the period under review as against Rs 19,021 million for the corresponding period of 2009.